Publications

(2023). Results from Expanded Access Programs: A Review of Academic Literature.

PDF Cite Code DOI

(2023). Results from Expanded Access Programs: A Review of Academic Literature. Drugs.

Cite DOI

(2023). The Ethics of Expanded Access Research. JAMA.

Cite DOI

(2022). The DRUG Access Protocol: Access Inequality and European Harmonisation. The Lancet Oncology.

Cite DOI

(2022). Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations. Frontiers in Pharmacology.

Cite DOI

(2022). Incremental Benefits of Novel Pharmaceuticals in the UK: A Cross-Sectional Analysis of NICE Technology Appraisals from 2010 to 2020. BMJ Open.

Cite DOI

(2022). The Predictive Value of a Positive Phase II ASH Abstract for Peer-Reviewed Publication and Progression to Phase III. Blood.

Cite DOI

(2022). Real-World Data from Expanded Access Programmes in Health Technology Assessments: A Review of NICE Technology Appraisals. BMJ Open.

Cite DOI

(2021). The Wider Perspective: Twenty Years of Clinical Trials in Myelodysplastic Syndromes. British Journal of Haematology.

Cite DOI

(2021). Two Decades of Targeted Therapies in Acute Myeloid Leukemia. Leukemia.

Cite DOI

(2021). [Expanded Access in The Netherlands: prescribing unregistered medicine].. Nederlands tijdschrift voor geneeskunde.

Cite

(2020). Response to Open Peer Commentary \"Making It Count: Extracting Real World Data from Compassionate Use and Expanded Access Programs\".. The American journal of bioethics : AJOB.

Cite DOI

(2020). Expanded Access as a Source of Real-World Data: An Overview of FDA and EMA Approvals. British Journal of Clinical Pharmacology.

Cite DOI

(2015). An example journal article. Journal of Source Themes, 1(1).

PDF Cite Code Slides